Please login to the form below

Not currently logged in
Email:
Password:

tasimelteon

This page shows the latest tasimelteon news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... Tasimelteon acts on melatonin MT1/MT2 receptors and

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics